biostudies-literatureRoeker LENCI NIH HHSnational cancer institute133-143https://www.ebi.ac.uk/biostudies/studies/S-EPMC9521791biostudies-literatureUnknown82(2)In this review, we examine the literature supporting treatment decision making in the front-line and relapsed/refractory settings for patients with chronic lymphocytic leukemia (CLL). In the front-line setting, novel-agent-based approaches, including continuous Bruton tyrosine kinase (BTK) inhibitor-based therapy and time-limited venetoclax with obinutuzumab, have demonstrated survival benefit over chemoimmunotherapy. While novel-agent-based front-line approaches are appropriate for most patients, fludarabine, cyclophosphamide, and rituximab (FCR) remains a consideration for a selected population of young patients with immunoglobulin heavy chain variable region gene (IGHV)-mutated disease because of the possibility of a prolonged remission following FCR. As front-line novel-agent-based appDrugsCurrent Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.PMC9521791P30 CA008748Roeker LEThompson MMato ARfalseCurrent Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.In this review, we examine the literature supporting treatment decision making in the front-line and relapsed/refractory settings for patients with chronic lymphocytic leukemia (CLL). In the front-line setting, novel-agent-based approaches, including continuous Bruton tyrosine kinase (BTK) inhibitor-based therapy and time-limited venetoclax with obinutuzumab, have demonstrated survival benefit over chemoimmunotherapy. While novel-agent-based front-line approaches are appropriate for most patients, fludarabine, cyclophosphamide, and rituximab (FCR) remains a consideration for a selected population of young patients with immunoglobulin heavy chain variable region gene (IGHV)-mutated disease because of the possibility of a prolonged remission following FCR. As front-line novel-agent-based app2022-01-01T00:00:00Z2022 Feb2025-04-19T14:19:53.699Z2025-02-19T04:46:04.945ZS-EPMC95217913493220710.1007/s40265-021-01657-0